Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from Protagonist Therapeutics’s reported figures.
Plus components not separately reported this period.
The source filing: Protagonist Therapeutics’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 4:17 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091123
FAQ
- What is Protagonist Therapeutics's EBIT?
- Protagonist Therapeutics (PTGX) reported EBIT of $158.77M in Q2 2026.
- How has Protagonist Therapeutics's EBIT changed year-over-year?
- Protagonist Therapeutics's EBIT increased by 477.6% year-over-year, from -$42.04M to $158.77M.
- What is the long-term trend for Protagonist Therapeutics's EBIT?
- Over 3 years (2021 to 2025), Protagonist Therapeutics's EBIT has grown at a 7.9% compound annual growth rate (CAGR), from -$125.85M to -$158.13M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Protagonist Therapeutics's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude